Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
bioRxiv ; 2024 May 13.
Article in English | MEDLINE | ID: mdl-38659858

ABSTRACT

Natural Killer (NK) cells can recognize and kill Mtb-infected cells in vitro, however their role after natural human exposure has not been well-studied. To identify Mtb-responsive NK cell populations, we analyzed the peripheral blood of healthy household contacts of active Tuberculosis (TB) cases and source community donors in an endemic region of Port-au-Prince, Haiti by flow cytometry. We observed higher CD8α expression on NK cells in putative resistors (IGRA- contacts) with a progressive loss of these circulating cells during household-associated latent infection and disease. In vitro assays and CITE-seq analysis of CD8α+ NK cells demonstrated enhanced maturity, cytotoxic gene expression, and response to cytokine stimulation relative to CD8α- NK cells. CD8α+ NK cells also displayed dynamic surface expression dependent on MHC I in contrast to conventional CD8+ T cells. Together, these results support a specialized role for CD8α+ NK cell populations during Mtb infection correlating with disease resistance.

2.
Pathogens ; 12(4)2023 Apr 18.
Article in English | MEDLINE | ID: mdl-37111499

ABSTRACT

BACKGROUND: Babesiosis, an intra-erythrocytic protozoan disease, is an emerging zoonotic parasitic disease worldwide. Cholesterol levels are correlated with severe infections, such as sepsis and COVID-19, and anecdotal reports suggest that high-density lipoprotein (HDL) cholesterol declines during acute babesiosis. Our aim was to describe the cholesterol levels in patients with acute babesiosis diagnosed in an endemic area in New York, hypothesizing that HDL levels correlate with the severity of infection. METHODS: We reviewed the medical records of adult patients with babesiosis diagnosed by identification of Babesia parasites on a thin blood smear and confirmed by polymerase chain reaction from 2013 to 2018, who also had available a lipid profile drawn at the time of clinical presentation. Additional lipid profile levels were considered as "baseline" if they were drawn within 2 months before or after the infection as part of routine care. RESULTS: A total of 39 patients with babesiosis had a lipid profile drawn on presentation. The patients were divided into two groups for comparison based on the treating physician's clinical decision: 33 patients who were admitted to the hospital and 8 patients who were evaluated as outpatients. A history of hypertension was more common in admitted patients (37% vs. 17%, p = 0.02). The median levels of low-density lipoprotein (LDL) and HDL were significantly reduced in admitted patients compared to non-admitted patients (46 vs. 76 mg/dL, p = 0.04; and 9 vs. 28.5 mg/dL, p = 0.03, respectively). In addition, LDL and HDL levels returned to baseline values following resolution of acute babesiosis. CONCLUSION: LDL and HDL levels are significantly reduced during acute babesiosis, suggesting that cholesterol depletion may predict disease severity. Pathogen and host factors may contribute to a reduction in serum cholesterol levels during acute babesiosis.

3.
Cell Host Microbe ; 31(3): 329-330, 2023 03 08.
Article in English | MEDLINE | ID: mdl-36893731

ABSTRACT

Recently in Nature Medicine, Musvosvi et al. analyzed single-cell T cell receptor (TCR) sequencing by grouping of lymphocyte interactions by paratope hotspots (GLIPH2) in a South African longitudinal cohort at high risk for tuberculosis. They find peptide antigen-specific T cells correlating with control of primary infection, potentially informing future vaccines.


Subject(s)
Mycobacterium tuberculosis , Tuberculosis , Humans , T-Lymphocytes , Tuberculosis/prevention & control , Receptors, Antigen, T-Cell , Peptides
4.
J Immunol ; 208(5): 1042-1056, 2022 03 01.
Article in English | MEDLINE | ID: mdl-35149530

ABSTRACT

Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that recognize microbial vitamin B metabolites and have emerging roles in infectious disease, autoimmunity, and cancer. Although MAIT cells are identified by a semi-invariant TCR, their phenotypic and functional heterogeneity is not well understood. Here we present an integrated single cell transcriptomic analysis of over 76,000 human MAIT cells during early and prolonged Ag-specific activation with the MR1 ligand 5-OP-RU and nonspecific TCR stimulation. We show that MAIT cells span a broad range of homeostatic, effector, helper, tissue-infiltrating, regulatory, and exhausted phenotypes, with distinct gene expression programs associated with CD4+ or CD8+ coexpression. During early activation, MAIT cells rapidly adopt a cytotoxic phenotype characterized by high expression of GZMB, IFNG and TNF In contrast, prolonged stimulation induces heterogeneous states defined by proliferation, cytotoxicity, immune modulation, and exhaustion. We further demonstrate a FOXP3 expressing MAIT cell subset that phenotypically resembles conventional regulatory T cells. Moreover, scRNAseq-defined MAIT cell subpopulations were also detected in individuals recently exposed to Mycobacterium tuberculosis, confirming their presence during human infection. To our knowledge, our study provides the first comprehensive atlas of human MAIT cells in activation conditions and defines substantial functional heterogeneity, suggesting complex roles in health and disease.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Lymphocyte Activation/immunology , Mucosal-Associated Invariant T Cells/immunology , Mycobacterium tuberculosis/immunology , Cell Proliferation , Cells, Cultured , Forkhead Transcription Factors/metabolism , Gene Expression Profiling , Granzymes/metabolism , Homeostasis/immunology , Humans , Interferon-gamma/metabolism , Mucosal-Associated Invariant T Cells/cytology , Receptors, Antigen, T-Cell/immunology , Ribitol/analogs & derivatives , Ribitol/immunology , Single-Cell Analysis , Transcriptome/genetics , Tumor Necrosis Factor-alpha/metabolism , Uracil/analogs & derivatives , Uracil/immunology
5.
Cells ; 10(10)2021 10 09.
Article in English | MEDLINE | ID: mdl-34685683

ABSTRACT

External validation in different cohorts is a key step in the translational development of new biomarkers. We previously described three host mRNA whose expression in peripheral blood is significantly higher (NPC2) or lower (DOCK9 and EPHA4) in individuals with TB compared to latent TB infection (LTBI) and controls. We have now conducted an independent validation of these genes by re-analyzing publicly available transcriptomic datasets from Brazil, China, Haiti, India, South Africa, and the United Kingdom. Comparisons between TB and control/LTBI showed significant differential expression of all three genes (NPC2high p < 0.01, DOCK9low p < 0.01, and EPHA4low p < 0.05). NPC2high had the highest mean area under the ROC curve (AUROC) for the differentiation of TB vs. controls (0.95) and LTBI (0.94). In addition, NPC2 accurately distinguished TB from the clinically similar conditions pneumonia (AUROC, 0.88), non-active sarcoidosis (0.87), and lung cancer (0.86), but not from active sarcoidosis (0.66). Interestingly, individuals progressing from LTBI to TB showed a constant increase in NPC2 expression with time when compared to non-progressors (p < 0.05), with a significant change closer to manifestation of active disease (≤3 months, p = 0.003). Moreover, NPC2 expression normalized with completion of anti-TB treatment. Taken together, these results validate NPC2 mRNA as a diagnostic host biomarker for active TB independent of host genetic background. Moreover, they reveal its potential to predict progression from latent to active infection and to indicate a response to anti-TB treatment.


Subject(s)
Disease Progression , Transcriptome/genetics , Tuberculosis/diagnosis , Tuberculosis/genetics , Vesicular Transport Proteins/genetics , Biomarkers/metabolism , Cohort Studies , Diagnosis, Differential , Gene Expression Regulation , Humans , RNA, Messenger/genetics , RNA, Messenger/metabolism , ROC Curve , Transcription, Genetic , Treatment Outcome , Tuberculosis/blood , Tuberculosis/pathology , Vesicular Transport Proteins/metabolism
6.
Nat Commun ; 12(1): 1141, 2021 02 18.
Article in English | MEDLINE | ID: mdl-33602926

ABSTRACT

The composition of the gastrointestinal microbiota influences systemic immune responses, but how this affects infectious disease pathogenesis and antibiotic therapy outcome is poorly understood. This question is rarely examined in humans due to the difficulty in dissociating the immunologic effects of antibiotic-induced pathogen clearance and microbiome alteration. Here, we analyze data from two longitudinal studies of tuberculosis (TB) therapy (35 and 20 individuals) and a cross sectional study from 55 healthy controls, in which we collected fecal samples (for microbiome analysis), sputum (for determination of Mycobacterium tuberculosis (Mtb) bacterial load), and peripheral blood (for transcriptomic analysis). We decouple microbiome effects from pathogen sterilization by comparing standard TB therapy with an experimental TB treatment that did not reduce Mtb bacterial load. Random forest regression to the microbiome-transcriptome-sputum data from the two longitudinal datasets reveals that renormalization of the TB inflammatory state is associated with Mtb pathogen clearance, increased abundance of Clusters IV and XIVa Clostridia, and decreased abundance of Bacilli and Proteobacteria. We find similar associations when applying machine learning to peripheral gene expression and microbiota profiling in the independent cohort of healthy individuals. Our findings indicate that antibiotic-induced reduction in pathogen burden and changes in the microbiome are independently associated with treatment-induced changes of the inflammatory response of active TB, and the response to antibiotic therapy may be a combined effect of pathogen killing and microbiome driven immunomodulation.


Subject(s)
Gastrointestinal Microbiome , Inflammation/microbiology , Inflammation/pathology , Tuberculosis/complications , Tuberculosis/microbiology , Adult , Algorithms , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Antitubercular Agents/pharmacology , Antitubercular Agents/therapeutic use , Bacterial Load/drug effects , Biodiversity , Case-Control Studies , Cohort Studies , Gastrointestinal Microbiome/drug effects , Gene Expression Regulation/drug effects , Humans , Inflammation/complications , Models, Biological , Reproducibility of Results , Tuberculosis/drug therapy , Tuberculosis/pathology
7.
Life Sci Alliance ; 4(2)2021 02.
Article in English | MEDLINE | ID: mdl-33361110

ABSTRACT

With a rising incidence of COVID-19-associated morbidity and mortality worldwide, it is critical to elucidate the innate and adaptive immune responses that drive disease severity. We performed longitudinal immune profiling of peripheral blood mononuclear cells from 45 patients and healthy donors. We observed a dynamic immune landscape of innate and adaptive immune cells in disease progression and absolute changes of lymphocyte and myeloid cells in severe versus mild cases or healthy controls. Intubation and death were coupled with selected natural killer cell KIR receptor usage and IgM+ B cells and associated with profound CD4 and CD8 T-cell exhaustion. Pseudo-temporal reconstruction of the hierarchy of disease progression revealed dynamic time changes in the global population recapitulating individual patients and the development of an eight-marker classifier of disease severity. Estimating the effect of clinical progression on the immune response and early assessment of disease progression risks may allow implementation of tailored therapies.


Subject(s)
Adaptive Immunity/immunology , COVID-19/immunology , Immune System Diseases/immunology , Immunity, Innate/immunology , SARS-CoV-2/immunology , Adult , Aged , Aged, 80 and over , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , COVID-19/epidemiology , COVID-19/virology , Disease Progression , Epidemics , Female , Humans , Immune System Diseases/diagnosis , Lymphocyte Subsets/immunology , Male , Middle Aged , SARS-CoV-2/physiology , Severity of Illness Index
8.
Front Immunol ; 12: 809937, 2021.
Article in English | MEDLINE | ID: mdl-35095900

ABSTRACT

Deep understanding of the SARS-CoV-2 effects on host molecular pathways is paramount for the discovery of early biomarkers of outcome of coronavirus disease 2019 (COVID-19) and the identification of novel therapeutic targets. In that light, we generated metabolomic data from COVID-19 patient blood using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. We find considerable changes in serum metabolome composition of COVID-19 patients associated with disease severity, and response to tocilizumab treatment. We built a clinically annotated, biologically-interpretable space for precise time-resolved disease monitoring and characterize the temporal dynamics of metabolomic change along the clinical course of COVID-19 patients and in response to therapy. Finally, we leverage joint immuno-metabolic measurements to provide a novel approach for patient stratification and early prediction of severe disease. Our results show that high-dimensional metabolomic and joint immune-metabolic readouts provide rich information content for elucidation of the host's response to infection and empower discovery of novel metabolic-driven therapies, as well as precise and efficient clinical action.


Subject(s)
Biomarkers/metabolism , COVID-19/immunology , COVID-19/metabolism , Metabolome/immunology , SARS-CoV-2/immunology , Adult , Aged , Biochemical Phenomena/immunology , Biomarkers/blood , COVID-19/blood , Female , Humans , Male , Metabolomics/methods , Middle Aged
9.
Infect Immun ; 89(1)2020 12 15.
Article in English | MEDLINE | ID: mdl-33077620

ABSTRACT

Mucosa-associated invariant T (MAIT) cells are an innate-like T cell subset in mammals that recognize microbial vitamin B metabolites presented by the evolutionarily conserved major histocompatibility complex class I (MHC I)-related molecule, MR1. Emerging data suggest that MAIT cells may be an attractive target for vaccine-induced protection against bacterial infections because of their rapid cytotoxic responses at mucosal services to a widely conserved bacterial ligand. In this study, we tested whether a MAIT cell priming strategy could protect against aerosol Mycobacterium tuberculosis infection in mice. Intranasal costimulation with the lipopeptide Toll-like receptor (TLR)2/6 agonist, Pam2Cys (P2C), and the synthetic MR1 ligand, 5-OP-RU, resulted in robust expansion of MAIT cells in the lung. Although MAIT cell priming significantly enhanced MAIT cell activation and expansion early after M. tuberculosis challenge, these MAIT cells did not restrict M. tuberculosis bacterial load. MAIT cells were depleted by the onset of the adaptive immune response, with decreased detection of granzyme B+ and gamma interferon (IFN-γ)+ MAIT cells relative to that in uninfected P2C/5-OP-RU-treated mice. Decreasing the infectious inoculum, varying the time between priming and aerosol infection, and testing MAIT cell priming in nitric oxide synthase 2 (NOS2)-deficient mice all failed to reveal an effect of P2C/5-OP-RU-induced MAIT cells on M. tuberculosis control. We conclude that intranasal MAIT cell priming in mice induces early MAIT cell activation and expansion after M. tuberculosis exposure, without attenuating M. tuberculosis growth, suggesting that MAIT cell enrichment in the lung is not sufficient to control M. tuberculosis infection.


Subject(s)
Mucosal-Associated Invariant T Cells/immunology , Mycobacterium tuberculosis/immunology , Respiratory Mucosa/immunology , Respiratory Mucosa/microbiology , Ribitol/analogs & derivatives , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/microbiology , Uracil/analogs & derivatives , Animals , Bacterial Load , Disease Models, Animal , Host-Pathogen Interactions/immunology , Immunity, Innate , Immunity, Mucosal , Lymph Nodes/immunology , Lymph Nodes/metabolism , Lymphocyte Activation , Mice , Mucosal-Associated Invariant T Cells/drug effects , Mucosal-Associated Invariant T Cells/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Respiratory Mucosa/drug effects , Ribitol/immunology , Ribitol/pharmacology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 6/metabolism , Tuberculosis, Pulmonary/metabolism , Tuberculosis, Pulmonary/pathology , Uracil/immunology , Uracil/pharmacology
10.
JCI Insight ; 3(19)2018 10 04.
Article in English | MEDLINE | ID: mdl-30282828

ABSTRACT

Innate immune responses that control early Mtb infection are poorly understood, but understanding these responses may inform vaccination and immunotherapy strategies. Innate T cells that respond to conserved bacterial ligands such as mucosal-associated invariant T (MAIT) and γδ T cells are prime candidates to mediate these early innate responses but have not been examined in subjects who have been recently exposed to Mtb. We recruited a cohort living in the same household with an active tuberculosis (TB) case and examined the abundance and functional phenotypes of 3 innate T cell populations reactive to M. tuberculosis: γδ T, invariant NK T (iNKT), and MAIT cells. Both MAIT and γδ T cells from subjects with Mtb exposure display ex vivo phenotypes consistent with recent activation. However, both MAIT and γδ T cell subsets have distinct response profiles, with CD4+ MAIT and γδ T cells accumulating after infection. Examination of exposed but uninfected contacts demonstrates that resistance to initial infection is accompanied by robust MAIT cell CD25 expression and granzyme B production coupled with a depressed CD69 and IFNγ response. Finally, we demonstrate that MAIT cell abundance and function correlate with the abundance of specific gut microbes, suggesting that responses to initial infection may be modulated by the intestinal microbiome.


Subject(s)
Immunity, Innate , Intraepithelial Lymphocytes/immunology , Mucosal-Associated Invariant T Cells/immunology , Mycobacterium tuberculosis/immunology , Tuberculosis/immunology , Adolescent , Adult , Child , Cohort Studies , Disease Resistance/immunology , Female , Gastrointestinal Microbiome/immunology , Humans , Immunity, Mucosal , Intestinal Mucosa/immunology , Intestinal Mucosa/microbiology , Lymphocyte Activation , Male , Middle Aged , Mycobacterium tuberculosis/isolation & purification , Respiratory Mucosa/immunology , Tuberculosis/microbiology , Young Adult
11.
Trop Doct ; 45(3): 164-7, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25824564

ABSTRACT

Little is known about diseases associated with altered mental status (AMS) in resource-limited settings. We studied adult medicine patients presenting with AMS in Lilongwe, Malawi and found that AMS and HIV infection were each significantly associated with mortality. It is therefore critical that evaluation and management in this patient population is improved.


Subject(s)
HIV Infections/epidemiology , Mental Disorders/epidemiology , Adult , Cohort Studies , Communicable Diseases/epidemiology , Communicable Diseases/mortality , Communicable Diseases/psychology , Female , HIV Infections/mortality , HIV Infections/psychology , Hospital Mortality , Humans , Malawi/epidemiology , Male , Mental Disorders/mortality , Mental Disorders/psychology , Poverty Areas , Prevalence , Retrospective Studies
12.
AIDS ; 26(2): 243-5, 2012 Jan 14.
Article in English | MEDLINE | ID: mdl-22008652

ABSTRACT

We conducted a case-control study to assess testosterone use as a primary risk factor for polycythemia in 21 HIV-infected men. Any testosterone use within 2 months of first elevated hemoglobin was associated with polycythemia (matched odds ratio 6.55; 95% confidence interval 1.83-23.4; P = 0.004) and intramuscular administration demonstrated a stronger association than topical use. No adverse cardiovascular or thrombotic events were observed. HIV-infected patients taking testosterone should undergo routine hematologic monitoring with adjustment of therapy when appropriate.


Subject(s)
Androgens/adverse effects , HIV Seropositivity/blood , Hormone Replacement Therapy/adverse effects , Polycythemia/blood , Polycythemia/chemically induced , Testosterone/adverse effects , Administration, Cutaneous , Androgens/administration & dosage , Androgens/blood , Case-Control Studies , HIV Seropositivity/complications , Hemoglobins/metabolism , Humans , Hypogonadism/drug therapy , Injections, Intramuscular , Male , Middle Aged , Odds Ratio , Polycythemia/epidemiology , Retrospective Studies , Risk Assessment , Testosterone/administration & dosage , Testosterone/blood , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...